摘要：

Copper(II) 2 (3,5-diisopropylsalicylate) 4 [Cu(II) 2 (3,5-DIPS) 4 ] and copper(II)(chloride) 2 [Cu(II)Cl 2 were used to treat γ-irradiated female C57BL/6 mice after irradiation at levels LD50/30 to compare their efficacy in facilitating recovery from radiation-induced systemic inflammatory disease accompanied by loss of body mass and in increasing survival of irradiated mice. Doses of 5, 10 or 20 μmol Cu(II)Cl 2 or 5, 10 or 20 μmol [Cu(II) 2 (3,5-DIPS) 4 ]/kg were administered subcutaneously 3 h after LD 50/30 irradiation and body mass and survival determined throughout the 30-day post-irradiation period compared with controls.Treatment with Cu(II) 2 (3,5-DIPS) 4 or Cu(II)Cl 2 facilitated recovery of radiation-induced systemic inflammatory disease, recovery of body mass, and increased survival. Treatment with 5, 10 or 20 (μmol [Cu(II) 2 (3,5-DIPS) 4 ]/kg produced a 44%, 67% or 44% increase in survival, respectively, compared with the vehicle-treated control group. Treatment with 5,10 or 20 μmol Cu(II)Cl 2 /kg produced a 7%, 21% or 29% increase in survival, respectively, compared with the vehicle-treated control group. The recovery of radiation-induced loss in body mass and an increase in survival document that both Cu(II) 2 (3,5-DIPS) 4 and Cu(II)Cl 2 are effective radiorecovery agents. In addition, Cu(II) 2 (3,5-DIPS) 4 is a more effective radiorecovery agent than Cu(II)Cl 2 .

展开